The future of healthcare is about to be unveiled at the highly anticipated JPMorgan Healthcare Conference. This event, a powerhouse gathering of biotech and pharma leaders, investors, and analysts, will set the tone for the industry's trajectory in 2026. But here's where it gets controversial...
While many feared the industry's outlook earlier in 2025, a series of landmark drug pricing deals with President Trump have offered a glimmer of hope. These agreements, coupled with a reprieve from sector-specific tariffs, have shifted the focus away from drug pricing policies for the first time in years. However, the industry still faces a significant challenge: a $300 billion patent cliff by the end of the decade.
The Patent Cliff: A Looming Threat?
Blockbuster drugs like Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer, and Merck's cancer immunotherapy Keytruda, are set to face competition from cheaper alternatives. This scenario has companies racing to offset potential revenue drops. For instance, Bristol Myers Squibb, with the highest exposure to the upcoming loss of exclusivity cycle, is gearing up for several data readouts this year, which will provide clarity on its post-2028 growth strategy.
The Alzheimer's Psychosis Trials: A Potential Game-Changer?
Investors will be keenly observing the upcoming Alzheimer's psychosis trials, known as the ADEPT program, for Bristol Myers Squibb's Cobenfy. JPMorgan analysts predict a reasonable probability of success for these studies, which could significantly impact the company's future.
Keytruda's Evolution: A Convenient Solution?
For Merck, the loss of exclusivity for Keytruda seems less daunting with the recent U.S. approval of a more convenient subcutaneous form of the drug. This new administration method is expected to protect a significant portion of Merck's U.S. sales of Keytruda, providing a much-needed boost.
Merck's Pipeline: What's in Store for 2026?
All eyes will be on Merck's drug pipeline updates, which may include initial results from a phase three trial on a flu prevention product from Cidara Therapeutics. Additionally, Merck is rumored to be in talks to acquire Revolution Medicines, a cancer drugmaker with a market cap exceeding $20 billion. This potential deal could further strengthen Merck's position in the industry.
Obesity: The Next Frontier in Pharma?
Obesity will undoubtedly be a hot topic at the conference, with Novo Nordisk and Eli Lilly leading the charge in GLP-1 pills. These companies, along with others like Amgen, AstraZeneca, and Pfizer, which recently acquired the obesity biotech Metsera, will face questions about their strategies in the weight loss drug market. Novo Nordisk's Wegovy pill, which began reaching patients this week, and Eli Lilly's oral GLP-1, orforglipron, expected to gain FDA approval in the first half of the year, are at the forefront of this discussion.
The Evolving GLP-1 Market: A Complex Landscape?
Both Novo Nordisk and Eli Lilly will likely face inquiries about the evolving dynamics of the GLP-1 market, including the direct-to-consumer channel and Medicare coverage for obesity drugs starting mid-year. This complex landscape will shape the future of these companies and the industry as a whole.
Stay tuned for our comprehensive coverage of the JPMorgan Healthcare Conference! And if you're attending, be sure to say hello! For any tips, suggestions, or story ideas, feel free to reach out to Annika at annika.constantino@versantmedia.com.
